3SBIO
0153013.5401.53% ( -0.210 )
Delay Closed: Oct 30, 16:08:08SSY Group falls 4% to 52-week low on US biotech investment curbs
HK Stock Market Update·3SBio hits 52-week low, declines 1% in Hong Kong
HK Stock Market Update·SSY Group falls 5% to 52-week low as biotech sector weakens
HK Stock Market Update·3SBio declines 1% to 52-week low as Hong Kong market weakens
HK Stock Market Update·Analyst Initiates Buy on 3SBio, Seeing Upside to HKD17.8 Target Price Driven by Robust Pipeline and Licensing Growth
Tip Ranks·- DBS Bank analyst Nico Chen initiated a buy rating on 3SBio with a target price of HKD 17.80. - The rating is supported by a diversified portfolio of over 40 marketed drugs, a strong research pipeline, and successful licensing deals such as the agreement with Pfizer. - Despite a 42.38% stock price decline over the past 6 months to HKD 14.360, the company's low forward P/E valuation and upcoming clinical data catalysts indicate significant upside potential.SSY Group climbs 3% as Hong Kong biotech sector extends rally
HK Stock Market Update·3SBio hits 52-week low as Hong Kong pharma sector weakens
HK Stock Market Update·SSY Group falls 2% to 52-week low as biotech sector weakens
HK Stock Market Update·SSY Group slips to 52-week low as biotech sector weakens
HK Stock Market Update·